ArticleOncotarget2016

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.

Carolina Simioni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.